Inflectra (Infliximab)

Infliximab is a monoclonal antibody that binds tightly to tumor necrosis factor‑alpha (TNF‑α), a key cytokine driving inflammation. By neutralising both soluble and membrane‑bound TNF‑α, it prevents activation of TNF receptors, thereby dampening the inflammatory cascade that underlies the listed autoimmune disorders.

The dosing regimen for Inflectra is individualized by the prescribing clinician based on the specific indication, patient weight, disease severity and response to therapy. Healthcare professionals determine the infusion dose, frequency and any subsequent adjustments.

Safety data for infliximab in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Clinicians should weigh potential benefits against risks and discuss options with the patient. Breastfeeding decisions should also be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the Inflectra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Inflectra (infliximab) is a chimeric monoclonal antibody administered intravenously, whereas other TNF‑alpha blockers such as adalimumab or etanercept are fully human or receptor‑fusion proteins given subcutaneously. Clinical efficacy is comparable across many indications, but differences in administration route, dosing frequency and immunogenicity may influence choice.

Inflectra must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Inflectra is supplied as a sterile solution for intravenous infusion. The infusion is performed in a clinical setting by qualified healthcare personnel, typically over a period of 2 hours for the initial dose, with subsequent infusions given at intervals defined by the treating physician.

The most serious risks include severe infections such as tuberculosis or opportunistic fungal infections, reactivation of hepatitis B, infusion‑related severe reactions, heart failure exacerbation, and rare malignancies like lymphoma. Patients should be monitored closely for any signs of these events.

Inflectra is contraindicated in patients with known hypersensitivity to infliximab or any component of the formulation, and in those with active serious infections. Caution is advised for individuals with moderate to severe heart failure, demyelinating disorders, or a history of malignancy.